Literature DB >> 8086508

Side effects of AZT prophylaxis after occupational exposure to HIV-infected blood.

S H Schmitz1, S Scheding, D Voliotis, H Rasokat, V Diehl, M Schrappe.   

Abstract

UNLABELLED: It was the objective of this study to document and evaluate AZT-induced short-term toxicity in healthy individuals. The study was designed as a longitudinal monocentric side-effect monitoring study with prospective data collection. It was carried out at the Cologne University Hospital. The study population comprised health care workers who were taking AZT prophylaxis after accidental exposure to HIV-infected blood. Fourteen individuals were included into the study; seven of them discontinued treatment prematurely, five due to severe subjective symptoms. In case of one worker AZT had to be stopped due to severe neutropenia (800 cells/microliters) with signs of upper respiratory tract infection. Four of 11 individuals taking AZT for at least 4 weeks developed neutropenia (2 WHO I, 1 WHO II, 1 WHO III). All other laboratory parameters stayed within normal range. In particular, no anemia was observed. IN
CONCLUSION: Compared with other studies more neutropenias are observed. Due to side effects 50% of the workers discontinued AZT administration prematurely. The data presented herein show that AZT causes considerable side effects which must be weighed against the potential protective antiviral effect.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8086508     DOI: 10.1007/bf01695694

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  9 in total

Review 1.  Pathophysiology and management of HIV-associated hematologic disorders.

Authors:  D T Scadden; L I Zon; J E Groopman
Journal:  Blood       Date:  1989-10       Impact factor: 22.113

2.  3'-Azido-3'-deoxythymidine in feline leukemia virus-infected cats: a model for therapy and prophylaxis of AIDS.

Authors:  L Tavares; C Roneker; K Johnston; S N Lehrman; F de Noronha
Journal:  Cancer Res       Date:  1987-06-15       Impact factor: 12.701

3.  Pre- and postexposure chemoprophylaxis: evidence that 3'-azido-3'-dideoxythymidine inhibits feline leukemia virus disease by a drug-induced vaccine response.

Authors:  L E Mathes; P J Polas; K A Hayes; C L Swenson; S Johnson; G J Kociba
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

4.  Zidovudine prophylaxis after accidental exposure to HIV: the Italian experience. The Italian Study Group on Occupational Risk of HIV Infection.

Authors:  V Puro; G Ippolito; E Guzzanti; I Serafin; G Pagano; F Suter; G Cristini; C Arici; G Angarano; F Soscia
Journal:  AIDS       Date:  1992-09       Impact factor: 4.177

5.  Surveillance of HIV infection and zidovudine use among health care workers after occupational exposure to HIV-infected blood. The CDC Cooperative Needlestick Surveillance Group.

Authors:  J I Tokars; R Marcus; D H Culver; C A Schable; P S McKibben; C I Bandea; D M Bell
Journal:  Ann Intern Med       Date:  1993-06-15       Impact factor: 25.391

6.  Suppression of mouse viraemia and retroviral disease by 3'-azido-3'-deoxythymidine.

Authors:  R M Ruprecht; L G O'Brien; L D Rossoni; S Nusinoff-Lehrman
Journal:  Nature       Date:  1986 Oct 2-8       Impact factor: 49.962

7.  The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial.

Authors:  D D Richman; M A Fischl; M H Grieco; M S Gottlieb; P A Volberding; O L Laskin; J M Leedom; J E Groopman; D Mildvan; M S Hirsch
Journal:  N Engl J Med       Date:  1987-07-23       Impact factor: 91.245

8.  The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial.

Authors:  M A Fischl; D D Richman; M H Grieco; M S Gottlieb; P A Volberding; O L Laskin; J M Leedom; J E Groopman; D Mildvan; R T Schooley
Journal:  N Engl J Med       Date:  1987-07-23       Impact factor: 91.245

9.  Postexposure prophylaxis with zidovudine suppresses human immunodeficiency virus type 1 infection in SCID-hu mice in a time-dependent manner.

Authors:  C C Shih; H Kaneshima; L Rabin; R Namikawa; P Sager; J McGowan; J M McCune
Journal:  J Infect Dis       Date:  1991-03       Impact factor: 5.226

  9 in total
  2 in total

Review 1.  Tolerability of postexposure antiretroviral prophylaxis for occupational exposures to HIV.

Authors:  L M Lee; D K Henderson
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

2.  Aptamer-based therapeutics: new approaches to combat human viral diseases.

Authors:  Ka-To Shum; Jiehua Zhou; John J Rossi
Journal:  Pharmaceuticals (Basel)       Date:  2013-11-25
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.